date:Aug 25, 2016
ation structure will not change the way that companies currently continue to consider a host of substances GRAS without notifying the FDA, meaning that theres no way to track exposure to certain unlisted ingredients. Other issues that remain with the process include the way in which the food industry uses industry-friendly GRAS panels to complete safety reviews of products and the fact that the FDA still does not have a system in place for the agency to reconsider a GRAS determination if new evi